Online citations, reference lists, and bibliographies.
← Back to Search

Persistent Lung Expansion After Pleural Talc Poudrage In Non-surgically Resected Malignant Pleural Mesothelioma.

O. Rena, R. Boldorini, E. Papalia, R. Mezzapelle, G. Baietto, Alberto Roncon, C. Casadio
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND To investigate the prognostic effect of persistent lung expansion after pleural talcage and other variables in non-surgically resected malignant pleural mesothelioma (MPM) patients. METHODS All consecutive patients submitted to video-assisted thoracoscopic (VAT) pleurodesis by talc poudrage for MPM between 2006 and 2011 were studied. The following parameters were prospectively recorded: age; sex; smoking history; asbestos exposure; C-reactive protein (CRP) levels; platelet (PLT) count; Eastern Cooperative Oncology Group performance status (ECOG PS); histologic subtype; clinical stage (cStage); chemotherapy; pleural fluid volume; and persistence of lung expansion at 3 months follow-up. Survival was assessed in June 2013. RESULTS A total of 172 patients were considered; 146 of 172 patients demonstrated a complete lung expansion at discharge, whereas only 85 of 172 patients had persistent expanded lung on the affected side at the 3-month follow-up chest x-ray. Median survival was 11.5 months (95% confidence interval [CI], 10% to 14%) and 2-year disease-specific survival was 13% (95% CI, 7% to 24%) for the entire cohort. Multivariate analysis showed that non-epithelioid histology (hazard ratio [HR], 2.81; 95% CI, 1.82% to 5.09%), pleural fluid recurrence (HR 2.54; 95% CI, 1.73% to 4.40%), cStage greater than II (HR 2.36; 95% CI, 1.50% to 4.32%), ECOG PS greater than 1 (HR 2.19; 95% CI, 1.26% to 4.23%), CRP greater than 5 mg/L (HR 2.01; 95% CI, 1.18% to 4.12%), and PLT count greater than 400,000 (HR 1.76; 95% CI 1.14% to 3.92%) were independent predictors of poor prognosis. CONCLUSIONS Persistent lung expansion after pleural talc poudrage and absence of fluid recurrence is demonstrated to be a stronger factor in predicting survival rather than clinical stage and other clinical variables in not surgically resected MPM patients.
This paper references
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1136/thoraxjnl-2012-203043
Pleurodesis outcome in malignant pleural mesothelioma
E. Fysh (2013)
Factors predictive of survival among 337 1183 Ann Thorac Surg RENA ET AL 2015;99:1177–83 MALIGNANT PLEURAL MESOTHELIOMA TREATMENT G E N E R A L T H O R A C IC patients with mesothelioma
JE Herndon (1984)
Is talc pleurodesis safe for young patient following primary spontaneous pneumothorax? Interact Cardiovasc
I Hunt (2007)
10.1016/j.lungcan.2011.12.009
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.1097/00000421-198212000-00014
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
10.1007/S00268-004-1046-6
Invited Commentary (DOI: 10.1007/s00268-004-1046-6)
Carol Tan (2004)
10.1007/s00408-011-9283-6
Tumor Type Influences the Effectiveness of Pleurodesis in Malignant Effusions
S. Bielsa (2011)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/S0090-3671(10)79654-3
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study
D. Jones (2010)
10.1016/J.CCM.2006.01.004
Management of malignant pleural mesothelioma.
S. West (2006)
10.1016/j.jtcvs.2012.09.023
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
M. Baud (2013)
10.1016/S1077-9108(08)79041-8
Malignant Pleural Mesothelioma: Surgical Management in 285 Patients
P. Bejarano (2009)
10.1002/ijc.26229
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
A. Marinaccio (2012)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1177/021849230601400307
Management of Malignant Mesothelioma by Decortication and Adjunct Phototherapy
C. P. Clarke (2006)
10.1510/ICVTS.2006.147546
Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax?
I. Hunt (2007)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1183/09031936.01.00225601
Management of malignant pleural effusions.
V. Antony (2001)
10.1159/000056291
Comparison of the Effectiveness of Some Pleural Sclerosing Agents Used for Control of Effusions in Malignant Pleural Mesothelioma: A Review of 117 Cases
A. Şenyiğit (2000)
10.1378/CHEST.110.6.1387
Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases.
J. Viallat (1996)
10.2217/LMT.14.26
Systematic review on pleurectomy/ decortication in the multimodality treatment of malignant pleural mesothelioma
S. Sestini (2014)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)



This paper is referenced by
10.1016/j.ejso.2017.02.010
Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.
P. Bertoglio (2017)
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
10.1016/j.lungcan.2019.09.003
Survival in patients with malignant pleural effusion undergoing talc pleurodesis.
Maged Hassan (2019)
10.1080/17476348.2020.1746647
Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis
Maged Hassan (2020)
10.1586/17476348.2016.1171147
The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence
P. Bertoglio (2016)
10.1016/j.jtcvs.2017.10.070
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
10.1016/j.ccm.2017.11.004
Malignant Pleural Effusion: From Diagnostics to Therapeutics.
R. Asciak (2018)
10.1007/s11748-020-01549-2
Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis
Eleftherios T. Beltsios (2020)
10.1183/13993003.00349-2018
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
10.21037/SHC.2018.05.05
Video-assisted thoracoscopic surgery in the management of mesothelioma
J. Ali (2018)
10.1080/09537104.2016.1246712
Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis
Y. Zhuo (2017)
10.21037/jovs.2017.05.05
Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.
P. Perikleous (2017)
10.21037/tlcr.2020.01.08
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
G. Woodard (2020)
10.1007/s00104-016-0186-1
Chirurgische Therapie des malignen Pleuramesothelioms
M. Schirren (2016)
Semantic Scholar Logo Some data provided by SemanticScholar